Watchlist

Watchlist
Apricus Biosciences, Inc. (APRI)
Apricus Biosciences, Inc. (APRI)
Apricus Biosciences' (APRI) CEO Richard Pascoe on Q3 2017 Results - Earnings Call Transcript
Apricus Biosciences, Inc. (APRI) Q3 2017 Earnings Conference Call November 02, 2017, 16:30 ET Executives Matthew Beck - VP, The Trout Group LLC Richard Pascoe - CEO, Principal Accounting Officer, Secretary and Director Kelly Deck - Executive Director of Finance Analysts Mit…
Equity offering registration roundup - healthcare
Recent S-3 filings: More news on: Ironwood Pharmaceuticals, Inc., Apricus Biosciences, Inc, Healthcare stocks news, Read more …
Apricus Biosciences (APRI) Presents At 2017 BIO Investor Forum - Slideshow
The following slide deck was published by Apricus Biosciences, Inc in conjunction with this Read more …
Apricus Biosciences (APRI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
The following slide deck was published by Apricus Biosciences, Inc in conjunction with this Read more …
PDUFA Run-Up Idea: Apricus Biosciences
Shares of Apricus Bisociences ( APRI ) have lost over 90% in the past three years and 50% in the past year alone. However, year-to-date shares have rebounded slightly by around 20%. APRI data by YCharts The stock popped on my radar recently when the company announced that the FDA has a…
Faison's Weekend Review And Scans
Over the past few months quite a few readers have been asking me where and how to scan and find ideas. From busted IPOs to insider buys, technical breakouts to unusual volume, there are plenty of ways to find interesting ideas that would take much longer than this piece can cover. Instead, I c…
3 Things In Biotech You Should Learn Today: September 1, 2017
Welcome to a new edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with recent findings in the biotech and pharma industries. Let's dive in! Pfizer heads toward first-line CML approval Of all the big competitors in the treatment of…
FDA accepts Apricus Bio's resubmitted Vitaros NDA, action date February 17; shares up 6% premarket
Nano cap Apricus Biosciences (NASDAQ: APRI ) perks up 6% premarket on average volume on the heels of its announcement that the FDA has accepted its resubmitted New Drug Application (NDA) for Vitaros (alprostadil), an on-demand topical cream for the treatment of erectile dysfunc…
Apricus resubmits U.S. marketing application for ED cream Vitaros
Apricus Biosciences ( APRI -0.7% ) has refiled a New Drug Application (NDA) with the FDA seeking approval for Vitaros (alprostadil), an on-demand topical cream for the treatment of erectile dysfunction. If accepted for review, the agency's action date should be sometime in Q1 2018. Mor…
Apricus Biosciences's (APRI) CEO Richard Pascoe on Q2 2017 Results - Earnings Call Transcript
Apricus Biosciences, Inc. (APRI) Q2 2017 Earnings Conference Call August 2, 2017 16:30 ET Executives Kelly Deck - Executive Director, Finance Richard Pascoe - CEO, Principal Accounting Officer, Secretary and Director Matthew Beck - VP, The Trout Group Analysts Yi Chen - HC …
Apricus Biosciences' (APRI) CEO Richard Pascoe on Q1 2017 Results - Earnings Call Transcript
Apricus Biosciences, Inc. (APRI) Q1 2017 Earnings Conference Call May 11, 2017, 16:30 ET Executives Kelly Deck - Executive Director, Finance Richard Pascoe - CEO, Principal Accounting Officer, Secretary and Director Matthew Beck - VP, The Trout Group Analysts Presentation …
Apricus Biosciences, Inc. (APRI)